Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSADMA Biologics, a biopharmaceutical and specialty globulin company, announced on April 1, 2019 that a new intravenous immunoglobulin drug ASCENIV™ developed by the company received FDA approval for its use in adults and adolescents for the treatment of primary humoral immunodefiency disease. The company is expecting to release the product commercially in the latter half of this year.
Global Intravenous Immunoglobulin Market Overview
Immunoglobulin is a large Y shaped protein which is a type of antibody created by plasma cells that are applied to neutralize pathogens such as viruses and pathogenic bacteria by the immune system. Immunoglobulin respond by binding to particular antigens by critically recognizing them and aiding in their destruction. This immunoglobulin comes in different varieties known as isotypes or classes. The antibodies are heavy globular plasma proteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer. Two types of immunoglobulin light chain occur in mammals, which are called lambda (λ) and kappa (κ). The increasing adoption of sedentary lifestyles, changing environmental conditions leading to higher cancer occurrence and growing long term illnesses is estimated to drive the growth of the intravenous immunoglobulin market over the forecast period i.e. 2019-2027.
Market Size & Forecast
The intravenous immunoglobulin market is anticipated to record a CAGR of 7.4% over the forecast period. New uses of intravenous immunoglobulin are being discovered through rigorous R&D activities which are expected to boost the revenue of the market in upcoming years. Additionally, many multi-national companies are concentrating towards new product advances in intravenous immunoglobulin. Currently, the market is observing a vibrant growth owing to increasing demand for highly effective health offerings in the market. The market is expected to grow strongly even more on the back of increasing neurological disorders and the applications of immunoglobulin in the treatment process. On the basis of regional platform, the global intravenous immunoglobulin market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
With a highly developed healthcare sector, North America is panned to observe substantial growth in the intravenous immunoglobulin market due to the growing rate of cancer prevalent population and long term disease suffering in the region. North America is further estimated to be followed by Europe in terms of consumption which can be attributed to the expanding geriatric population across the region and the presence of high aging population prevalent countries such as Greece, Italy and others over the forecast period. CLICK TO DOWNLOAD SAMPLE
Asia Pacific is expected to drive the demand and positively impact the market growth over the forecast period on account of increasing healthcare expenditure across the region along with rising R&D activities and growing governmental support for advancements in healthcare offerings around the countries such as India, China, Japan and others.
Growth Drivers & Challenges
Increasing Immunodeficiency Diseases
On the back of high prevalence rate of malnutrition, poor sanitary conditions and human immune deficiency virus (HIV) infection, the number of immunodeficiency diseases is at a rise which is further anticipated to propel the intravenous immunoglobulin market over the forecast period. Additionally, increasing incidence rate of various types of cancers with cancer positioned as the second leading cause of deaths around the globe and with an estimated rise to 18.1 million new cases of cancer in the year 2018 as per WHO is driving the Intravenous Immunoglobulin market across the globe. Besides, patients with long-lasting serious disorders are increasing, resulting in rise in number of cancer patients, subsequently contributing towards the positive growth of the market. Moreover, growing number of hemophilic patients along with advent of enhanced purification techniques for better plasma yield are anticipated to contribute significantly towards the growth of the market over the forecast period. Furthermore, increasing prevalence rate of hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP) and others are estimated to expand the applications of intravenous immunoglobulin around the world.
Expanding Healthcare Infrastructure & Expenditure
On account of increasing current health expenditure per capita, PPP (current international $) from $1,035.026 in 2010 to $1,300.114 in 2015 around the world, the intravenous immunoglobulin market is expected to grow during the forecast period. Increasing production of immunoglobulin due to the emergence of advanced technologies along with rapid increase in the number of neurological disorders is expected to augment the market growth. Furthermore, increasing aging population around the world at a rapid incremental rate is also expected to propel the intravenous immunoglobulin market over the forecast period.
Rising use of off-label indications and increasing adoption of IVIG treatments are further estimated to drive the intravenous immunoglobulin market across the globe. On account of increasing acquired and primary immunodeficiency diseases due to obesity & antibody deficiency disorders, the demand for IVIG therapies has been propelling on the back of their high affectivity and are the only available treatment option in the market.
Association of Varying Side Effects
However, the various side effects associated with every type of immunoglobulin product from patient to patient along with relative stringent government regulations is estimated to serve as restraining factor in the growth of the intravenous immunoglobulin market during the forecast period.
Restraints
Harmful Side-Effects of IVIg Therapy to Restrict the Market Growth
The use of intravenous immunoglobulins might produce certain side-effects that are harmful for the patients. These include back pain, nausea, headache and chills among others. In order to control the side-effects of this treatment, strict government policies exist which are further estimated to limit the market growth during the forecast period.
Market Segmentation
Our-in depth analysis of the global intravenous immunoglobulin market includes the following segments:
By Application
By Immunoglobulin Type
By End-User
By Region
Global intravenous immunoglobulin market is further classified on the basis of region as follows:
Key Players
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2020 Research Nester. All Rights Reserved
